RxDoctor Payments DataLook up a doctor →

Caroline Huang, MD

Endocrinology, Diabetes & Metabolism · Arlington, VANPI 1508804790

Payments from drug & device makers

$34,364in general payments, 2019–2025

Across 441 payments — averaging $77.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Xeris Pharmaceuticals, Inc.$17K
  • Novo Nordisk AS$4K
  • Dexcom, Inc.$3K
  • Abbott$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • plus $7K from 47 others

What the payments were for

  • Speaking & faculty fees$16,83855%
  • Travel & lodging$3,44511%
  • Food & beverage$9,89533%
  • Education$680%
  • Gifts$1190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,364 in reported general payments places this provider in the 85th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.

See all endocrinology, diabetes & metabolism providers in Virginia

Medicare billing

Part B allowed, 2024
$133,310
Medicare patients
499
Services billed
2,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide103$191,530
JardianceEmpagliflozin126$143,272
ForteoTeriparatide22$109,206
MounjaroTirzepatide65$105,023
TrulicityDulaglutide33$59,169
Synjardy XrEmpagliflozin/Metformin Hcl34$58,458
TymlosAbaloparatide19$48,199
JanuviaSitagliptin Phosphate33$41,630
FarxigaDapagliflozin Propanediol27$40,842
RybelsusSemaglutide19$36,660
Tresiba Flextouch U-200Insulin Degludec17$17,802
SynthroidLevothyroxine Sodium187$17,704
TradjentaLinagliptin17$16,192
Soliqua 100-33Insulin Glargine/Lixisenatide17$15,361
Humalog Kwikpen U-100Insulin Lispro53$14,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCForteo, Mounjaro, Trulicity, Humalog$1,034$279,287134 claims
Novo NordiskOzempic, Rybelsus$1,118$228,189122 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$431$217,921177 claims
MerckJanuvia, Janumet$24$52,04645 claims
Radius Health, Inc.Tymlos$122$48,19919 claims
AstraZenecaFarxiga$169$40,84227 claims
AbbVieSynthroid$85$17,704187 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$644$15,36117 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$514$3,275242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.

Other endocrinology, diabetes & metabolism in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →